Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity

REFERENCES

• Stavudine approved under accelerated drug-approval pro-cess. Am J Hosp Pharm. 1994;51:2087-2091.
   Google Scholar
• Hurst M, Noble S. Stavudine: an update of it use in the treatment of HIV infection. Drugs. 1999;58:919–949.
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syn-drome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659–1667.
   PubMed Web of Science ®Google Scholar
• Melial S, John M, Moore C, James I, McKinnon E. Contri-bution of nucleoside analogue reverse transcriptase inhibi-tors to subcutaneous fat wasting in patients with HIV infec-tion. AIDS. 2000;14:1309–1316.
   PubMed Web of Science ®Google Scholar
• Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associ-ated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome. AIDS. 2000;14:F25–F32.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Casula M, Weverlingz G, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allo-cated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385–393.
   PubMed Web of Science ®Google Scholar
• Bogner J, Vielhauer V, Beckmann R, et al. Stavudine ver-sus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237–244.
   PubMed Web of Science ®Google Scholar
• Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with pro-tease inhibitors: a prospective cohort study. Lancet. 2001;357:592–598.
   PubMed Web of Science ®Google Scholar
• Mokrzycki M, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis. 2000,30:198–200.
   PubMed Web of Science ®Google Scholar
• Garcia-Benayas T, Blanco F, de la Cruz J, et al. Replacing stavudine by abacavir reduces lactate levels and may im-prove lipoatrophy. AIDS. 2003;17:921–924.
   PubMed Web of Science ®Google Scholar
• Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029–1036.
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V, Philip G. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regi-mens. J Acquir Immun Defic Syndr. 2003;33:544–546.
   PubMed Web of Science ®Google Scholar
• Milinkovic A, Lopez S, Vidal S, et al. A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. Pre-sented at: 12th Conference on Retroviruses and Opportu-nistic Infections; February 22–25, 2005; Boston, Massa-chusetts. Abstract 857.
   Google Scholar
• Holguin A, Dietrich U, Immelmann A, Soriano V. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group. Antivir Ther. 1998,3:183–186.
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Tardy J. Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review. AIDS Rev. 2003;5:80–86.
   PubMedGoogle Scholar
• Bocket L, Yazdanpanah Y, Ajana F, et al. Thymidine ana-logue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. J Antimicrob Chemother. 2004;53:89–94.
   PubMed Web of Science ®Google Scholar
• Villalba N, Soriano V, Gomez-Cano M, Castilla J, Mas A, Gonzalez-Lahoz J. Short-term efficacy and safety of stavudine in pretreated HIV infected patients. Antivir Ther. 1997;2:185–189.
   PubMedGoogle Scholar
• Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effective-ness and safety of a generic fixed-dose combination of nevirapine, stavudine and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29–34.
   PubMed Web of Science ®Google Scholar
• Kakuda T. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial tox-icity. Clin Ther. 2000;22:685–708.
   PubMed Web of Science ®Google Scholar
• de Mendoza C, de Ronde A, Smolders K, et al. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses. 2004;20:271–273.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Casula M, Weverlingz G, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in H1V-1-infected patients randomly allo-cated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385–393.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Garcia-Benayas T, Rendon A, Rodriguez-Novoa S, Soriano V. Combinations of nucleoside/nucle-otide analogues for HIV therapy. AIDS Rev. 2004;6:234–243.
   PubMed Web of Science ®Google Scholar
• Hanvanich M, et al. Reduction of d4T improves lipoatrophy without virologic failure. Presented at: 2nd IAS Conference; 2003; Paris. Abstract 749.
   Google Scholar
• Dudley M, Graham K, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis. 1992166: 480–485.
   Google Scholar
• Fisher M. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine. AIDS. 1998;12(suppl):9–16.
   Google Scholar
• Yeni P, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:266–268.
   PubMed Web of Science ®Google Scholar
• Dybul M, Fauci A, Bartlett J, et al. Guidelines for using antiretroviral agents among HIV-infected adults and ado-lescents. Ann Intern Med. 2002;137:381–433.
   PubMed Web of Science ®Google Scholar
• Fischl M, Parker C, Pettinelli C, et al. A randomized con-trolled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1009–1014.
   PubMed Web of Science ®Google Scholar
• Koegl C. Low dose stavudine: as effective as standard dose but less side effects. Presented at: 9th European AIDS Conference; 2003; Warsaw. Abstract 9.8/5.
   Google Scholar
• del Pierre C. Lowering stavudine dosages does not com-promise antiviral efficacy in HIV-infected patients. Pre-sented at: 9th European AIDS Conference; 2003; Warsaw. Abstract 9.4/2.
   Google Scholar
• Skowron G. Biologic effects and safety of stavudine: over-view of phase I and 11 clinical trials. J Infect Dis. 1995;171\(suppl 2):113–117.
   PubMed Web of Science ®Google Scholar
• Petersen E, Ramirez-Ronda C, Hardy W, et al. Dose-re-lated activity of stavudine in patients infected with HIV. J Infect Dis. 1995;171\(suppl 2):131–139.
   Web of Science ®Google Scholar
• Cote H, Brumme Z, Craib K, et al. Changes in mitochon-drial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811–820.
   PubMed Web of Science ®Google Scholar